An algorithm for the selection of optimal drug treatment of a patient with pulmonary arterial hypertension.   Although treprostinil is approved for Functional Class IV patients, most experts would initiate therapy with intravenous epoprostenol, and consider transitioning to treprostinil once the patients has stabilized, or in circumstances where epoprostenol therapy results in intolerable side effects or recurrent catheter infections.